At the news
? BULLISHIMPACT 7/10 8-K filed Feb 26, 2026 at 07:32 ET
Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2025, with revenue growth of 13% and 24% YoY respectively, driven by significant growth in its ADHD business (Jornay PM) and durable performance in its pain portfolio. The company reaffirmed its 2026 guidance and strengthened its balance sheet through a new $980 million credit facility and $25 million in share repurchases.
- Generated record quarterly net revenues of $205.4 million (up 13% YoY) and full-year net revenues of $780.6 million (up 24% YoY)
- Jornay PM net revenue grew 57% YoY in Q4 and 48% YoY for the full year
- Pain portfolio net revenues grew 5% YoY in Q4 and 6% YoY for the full year
- Reaffirmed full-year 2026 guidance with product revenues of $805-825 million and adjusted EBITDA of $455-475 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access